Chronic treatment with cholinesterase inhibitors increases [alpha]2-adrenoceptors in rat brain
dc.contributor.author | Hollingsworth, Peggie J. | en_US |
dc.date.accessioned | 2006-04-07T20:13:29Z | |
dc.date.available | 2006-04-07T20:13:29Z | |
dc.date.issued | 1988-08-24 | en_US |
dc.identifier.citation | Hollingsworth, Peggie J. (1988/08/24)."Chronic treatment with cholinesterase inhibitors increases [alpha]2-adrenoceptors in rat brain." European Journal of Pharmacology 153(2-3): 167-173. <http://hdl.handle.net/2027.42/27177> | en_US |
dc.identifier.uri | http://www.sciencedirect.com/science/article/B6T1J-4746BGV-TT/2/d632306c58051db9c95500bd59c957d1 | en_US |
dc.identifier.uri | https://hdl.handle.net/2027.42/27177 | |
dc.identifier.uri | http://www.ncbi.nlm.nih.gov/sites/entrez?cmd=retrieve&db=pubmed&list_uids=2846316&dopt=citation | en_US |
dc.description.abstract | The specific binding of [3H]clonidine to [alpha]2-adrenoceptorson neural membranes isolated from various brain areas was determined with rats treated for 7-14 days with the cholinesterase inhibitors neostigmine, triorthocresyl phosphate (TOCP), diisopropylfluorophosphate (DFP) and paraoxon, or with vihicle. Treatment with all four inhibitors increased the number of clonidine binding sites in various brain areas. In those areas which demonstrated significant increases in [3H]clonidine binding, there was also a significant inhibition of acetylcholinesterase activity. The possibility is discussed that increases in brain [alpha]2-adrenoceptors are related to the alterations in mood seen in individuals chronically exposed to organophosphorus cholinesterase inhibitors. | en_US |
dc.format.extent | 579789 bytes | |
dc.format.extent | 3118 bytes | |
dc.format.mimetype | application/pdf | |
dc.format.mimetype | text/plain | |
dc.language.iso | en_US | |
dc.publisher | Elsevier | en_US |
dc.title | Chronic treatment with cholinesterase inhibitors increases [alpha]2-adrenoceptors in rat brain | en_US |
dc.type | Article | en_US |
dc.rights.robots | IndexNoFollow | en_US |
dc.subject.hlbsecondlevel | Pharmacy and Pharmacology | en_US |
dc.subject.hlbtoplevel | Health Sciences | en_US |
dc.description.peerreviewed | Peer Reviewed | en_US |
dc.contributor.affiliationum | Department of Pharmacology, The University of Michigan Medical School, Ann Arbor, MI 48109, U.S.A. | en_US |
dc.identifier.pmid | 2846316 | en_US |
dc.description.bitstreamurl | http://deepblue.lib.umich.edu/bitstream/2027.42/27177/1/0000175.pdf | en_US |
dc.identifier.doi | http://dx.doi.org/10.1016/0014-2999(88)90603-6 | en_US |
dc.identifier.source | European Journal of Pharmacology | en_US |
dc.owningcollname | Interdisciplinary and Peer-Reviewed |
Files in this item
Remediation of Harmful Language
The University of Michigan Library aims to describe library materials in a way that respects the people and communities who create, use, and are represented in our collections. Report harmful or offensive language in catalog records, finding aids, or elsewhere in our collections anonymously through our metadata feedback form. More information at Remediation of Harmful Language.
Accessibility
If you are unable to use this file in its current format, please select the Contact Us link and we can modify it to make it more accessible to you.